O
Oxford Biomedica
Viral vector development and manufacturing for therapies
About Oxford Biomedica
Oxford Biomedica (OXB) is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company was founded in 1995 as a spin-out from the University of Oxford by Professor Alan Kingsman and Dr. Susan Kingsman, leveraging their expertise in virology and gene expression. It went public via an initial public offering on the Alternative Investment Market in 1996.
OXB operates on a business-to-business (B2B) model, serving pharmaceutical and biotechnology companies ranging from small startups to large corporations. The company's core business revolves around providing viral vector development and manufacturing services, which are crucial components for its clients' gene and cell therapy products. This includes expertise in lentivirus, adeno-associated virus (AAV), and adenovirus vectors. Its revenue is generated through these contract services, supporting clients from early-stage development and clinical trials to full-scale commercial manufacturing. The company has recently transformed into a 'pure-play' CDMO to focus entirely on these client-centric services, a move that included significant operational streamlining.
The company's key offerings include its proprietary LentiVector™ platform and the inAAVate™ platform for AAV vectors, providing end-to-end solutions from process development to manufacturing. OXB has established numerous high-profile partnerships with companies like Novartis, Sanofi, and GSK. A notable collaboration was with the Jenner Institute and AstraZeneca to manufacture the COVID-19 vaccine. The company maintains state-of-the-art facilities in the UK, France, and the US to serve its global client base.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2008
- Outcome tier
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
News
Open roles
Oxford Biomedica in the Oxford ecosystem
The Oxford Biomedica office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
Novo Ventures
Serum Institute of India
Transgene
Oaktree Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
21 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oxford Biomedica on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oxford Biomedica on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

